1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Hangzhou Tigermed Consulting Co., Ltd

Hangzhou Tigermed Consulting Co., Ltd

HNGZY
Hangzhou Tigermed Consulting Co., LtdUS flagOther OTC
4.45
USD
- -
- -
6.86BMarket Cap
Hangzhou Tigermed Consulting Co., Ltd
HNGZY
(Other OTC)

Recent

price

4.45

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.26
0.4
0.48
0.52
0.96
1.47
1.67
2.29
3.07
3.76
4.01
6
8.19
8.53
7.66
8
7.46
Revenue per Share
0.07
0.1
0.13
0.15
0.19
0.24
0.2
0.41
0.63
1.13
2.2
3.31
2.32
2.34
0.47
1.04
0.34
Basic EPS, GAAP
0.04
0.05
-0.01
0.06
0.01
0.15
0.19
0.36
0.57
0.57
1.06
1.22
1.05
0.97
0.86
1.06
-0.29
Free Cash Flow per Basic Share
- -
- -
- -
0.07
0.07
0.07
0.08
0.08
0.17
0.36
0.34
0.33
0.57
0.68
0.74
0.4
0.98
Dividend per Share
0.14
0.23
0.34
0.44
0.71
1.21
1.29
1.57
2.23
3.42
5.19
7.65
9.41
11.15
11.08
11.93
11.11
Book Value per Share
0.18
0.26
1.26
1.13
0.86
0.89
1.74
2.35
2.95
5.73
20.46
21.39
22.96
24.64
23.78
23.97
23.44
Tangible Book Value per Share
476
482
535
641
649
651
703
738
749
745
795
868
865
865
862
854
871
Basic Weighted Avg Shares
123
193
254
337
625
957
1,175
1,687
2,301
2,803
3,192
5,214
7,085
7,384
6,603
6,833
6,495
Sales/Revenue/Turnover
28.48
28.77
27.12
27.32
26.32
22.95
15.22
23.85
23.05
26.79
27.55
26.43
25.56
23.78
16.17
9.76
11.2
Operating Margin (%)
2
3
4
4
12
31
35
31
58
43
145
189
265
306
324
327
- -
Depreciation Expense
32
48
68
94
125
156
141
301
472
842
1,750
2,874
2,007
2,025
405
888
296
Net Income, GAAP
11.18
15.54
13.81
14.49
20.54
21.03
26.07
22.97
16.38
10.45
8.55
7.95
12.13
13.61
32.6
19.75
39.32
Effective Tax Rate (%)
25.81
24.73
26.64
27.95
20.09
16.33
11.98
17.84
20.52
30.02
54.81
55.13
28.32
27.42
6.14
12.99
4.55
Profit Margin (%)
67
105
622
629
400
217
659
612
385
1,560
10,507
8,439
7,378
7,205
2,638
3,342
2,811
Working Capital
- -
- -
- -
- -
12
7
16
17
110
172
279
407
734
857
723
964
942
LT Debt
96
146
694
755
917
1,066
1,840
2,801
3,272
5,521
17,858
20,605
22,681
24,454
24,064
24,256
23,964
Total Equity
43.29
38.37
14.11
10.81
13.26
13.57
7.82
12
12.35
12.59
6.44
6.29
6.68
5.67
2.62
2.02
1.61
Return on Invested Capital (%)
61.12
52.24
41.84
34.55
21.54
14.72
10.74
17.86
19.46
19.1
27.14
28.73
14.9
13.13
2.84
6.75
2.06
Return on Capital (%)
64.89
54.89
46.27
40.48
33.73
25.04
16.59
29.12
33.37
39.91
52.46
53.38
27.14
22.76
4.22
9
3.06
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
2,111
2,087
1,651
LT Borrowings
324
582
557
LT Finance Leases
399
383
385
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
865
865
861
Market Capitalization
25,427
25,363
24,963

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
6,300
5,895
6,206
Cash, Cash Equivalents & STI
2,130
1,675
1,820
Accounts Receivable, Net
1,360
1,155
1,288
Inventories
32
36
44
Total Current Liabilities
3,662
3,636
3,396
Payables & Accruals
- -
- -
- -
ST Debt
2,111
2,087
1,651
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
46.63%
6.5%
0.8%
Free Cash Flow
30.96%
2.81%
22.05%
Net Income, GAAP
42.11%
14.83%
119.15%
Sales/Revenue/Turnover
23.48%
19.27%
3.48%
Total Cash Common Dividend
30.43%
12.03%
-46.48%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,660
1,698
1,709
1,536
6,603
2025
1,564
1,686
1,807
- -
6,833
2026
1,801
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.27
- -
- -
- -
0.47
2025
0.19
- -
- -
- -
1.04
2026
0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
- -
- -
- -
0.74
2025
0.03
- -
- -
- -
0.4
2026
0.02
- -
- -
- -
- -
Similar Companies
NervGen Pharma Corp. Common stock (NGEN)
Hansa Biopharma AB (publ) (HNSA.ST)
Liminatus Pharma, Inc. Class A Common Stock (LIMN)
Silverback Therapeutics, Inc. (SBTX)
Acasti Pharma Inc. (ACST.V)
Kaleido Biosciences, Inc. (KLDO)
Business
Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ/3347.HK; OTC:HNGZY) operates as a leading global contract research organization providing integrated research and development solutions for the biopharmaceutical and medical device industries; core services encompass preclinical development including medicinal chemistry, compound screening, drug metabolism and pharmacokinetics, safety and toxicology, bioanalytical, and chemistry manufacturing controls; clinical development offerings such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, site management, medical device and in vitro diagnostics trials, multi-region clinical trials, and vaccine trials; and additional capabilities like pharmacovigilance, medical translation, quality assurance, GMP consulting, central laboratories, functional service provision, patient recruitment, electronic data capture systems, and remote follow-up. The company serves pharmaceutical, biotechnology, and medical device firms across phases I to IV of clinical trials, with technical support for registration, on-site services, and data analysis; it targets innovative drugs, generics, and devices in therapeutic areas including endocrinology, nervous system diseases, immune disorders, neoplasms, and more. Founded on December 15, 2004, and headquartered in Hangzhou, China, Tigermed maintains an international headquarters in Hong Kong and operates through over 100 subsidiaries and 180 locations in more than 50 countries across Asia-Pacific, Europe, North and South America, and Africa, employing over 10,000 staff. Recent developments include the 2023 opening of its Hong Kong international headquarters to bolster global coordination; the 2024 full-year results announcing 7.3% growth in new bookings, 12% backlog increase, and support for 28 Class I new drug and 6 innovative medical device approvals alongside 831 ongoing drug trials and 614 device/IVD projects; acquisition of Medical Edge in 2024; and completion of the acquisition of Japanese CRO Micron Inc. in July 2025, integrating it into Tigermed Japan to enhance medical imaging, clinical services, and Asia-Pacific expansion.